Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function (AB-CD-10)

This study has been completed.
Sponsor:
Collaborator:
University of Copenhagen
Information provided by (Responsible Party):
Carsten Dirksen, Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT01559779
First received: March 19, 2012
Last updated: June 9, 2014
Last verified: June 2014
  Purpose

The study aims at describing the acute and subacute changes after Roux-en-Y (RYGB) gastric bypass in insulin secretion from the beta cell and glucagon secretion from the alpha cell as well as the stimulatory effect of the incretins on the pancreatic islets. RYGB is a bariatric procedure that changes the gastrointestinal anatomy and has been demonstrated to cause remission of type 2 diabetes shortly after the operation, before any significant weight loss. The altered transit of nutrient through the gastrointestinal tract after the operation is thought to play a key role in this remission and studies have shown significant changes in the secretion of gut hormones, namely the incretin hormone glucagon-like peptide-1 (GLP-1). However it is unknown whether the secretory function of the pancreatic islets as well as the stimulatory effect of the incretin hormones is changes postoperatively.


Condition
Obesity

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Effect of Gastric Bypass Surgery on the Beta- and Alpha Cells Secretory Function and the Insulinotropic Effect of the Incretin Hormones

Resource links provided by NLM:


Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • Change in beta cell function [ Time Frame: Before and 1 week and 3 months after surgery ] [ Designated as safety issue: No ]
    Change in first and second phase insulin response, disposition index, and acute insulin secretion in response to a non-glucose stimulus

  • Insulinotropic effect of incretin hormones [ Time Frame: Before and 1 week and 3 months after surgery ] [ Designated as safety issue: No ]
    Change in first and second phase insulin response during GLP-1 and GIP infusion compared to saline


Secondary Outcome Measures:
  • Change in alpha cell function [ Time Frame: Before and 1 week and 3 months after surgery ] [ Designated as safety issue: No ]
    Change in glucagon secretion in response to glucose and non-glucose stimuli


Biospecimen Retention:   Samples Without DNA

Plasma and serum specimens are retained


Enrollment: 11
Study Start Date: November 2010
Study Completion Date: December 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Normal glucose tolerance
Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects are recruited from the population undergoing gastric bypass surgery at Hvidovre Hospital

Criteria

Inclusion Criteria:

  • Normal glucose tolerance
  • Age > 18 years
  • BMI > 40 or > 35 if combined with hypertension or obstructive sleep apnoea
  • Caucasian
  • Normal hemoglobinaemia
  • Signed informed consent

Exclusion Criteria:

  • Major psychiatric disorder
  • Alcohol or drug abuse
  • Major hearth or pulmonary disease
  • Previous major abdominal disease (e.g. peritonitis, large hernia)
  • Pregnancy/lactation
  • Treatment with GLP-1 analogs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01559779

Locations
Denmark
Dpt. of Endocrinology (215) at Hvidovre Hospital
Hvidovre, Copenhagen, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
University of Copenhagen
Investigators
Principal Investigator: Carsten Dirksen, MD Hvidovre University Hospital
  More Information

No publications provided by Hvidovre University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Carsten Dirksen, MD PhD student, Hvidovre University Hospital
ClinicalTrials.gov Identifier: NCT01559779     History of Changes
Other Study ID Numbers: AB-CD-10
Study First Received: March 19, 2012
Last Updated: June 9, 2014
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics
Denmark: Danish Dataprotection Agency

Keywords provided by Hvidovre University Hospital:
Obesity
Roux-en-Y gastric bypass
Incretin hormones
Beta cell function

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Gastric Inhibitory Polypeptide
Incretins
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014